Literature DB >> 15107198

Bupropion in the management of apathy.

C Corcoran1, M L Wong, V O'Keane.   

Abstract

We report on three males with prominent apathy as part of the symptom complex of depression or organic brain disease. Significant clinical responses were observed following treatment with bupropion, an antidepressant with dopamine (DA) reuptake activity. We present clinical evidence in support of the hypothesis that remission in these patients occurred as a consequence of bupropion-induced increases in central DA neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15107198     DOI: 10.1177/0269881104043284

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  13 in total

Review 1.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 2.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

3.  Treatment of Apathy in Huntington's Disease and Other Movement Disorders.

Authors:  Ashok Krishnamoorthy; David Craufurd
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

4.  Abulia following an episode of cardiac arrest.

Authors:  Vismay Dinesh Naik
Journal:  BMJ Case Rep       Date:  2015-07-01

Review 5.  Apathy and the basal ganglia.

Authors:  Richard Levy; Virginie Czernecki
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

6.  Apathy syndrome treated successfully with modafinil.

Authors:  Einstein Francisco Camargos; Juliana Lima Quintas
Journal:  BMJ Case Rep       Date:  2011-11-15

7.  Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?

Authors:  Laura B Zahodne; Oscar Bernal-Pacheco; Dawn Bowers; Herbert Ward; Genko Oyama; Natlada Limotai; Frances Velez-Lago; Ramon L Rodriguez; Irene Malaty; Nikolaus R McFarland; Michael S Okun
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

8.  Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).

Authors:  Lea T Drye; Roberta W Scherer; Krista L Lanctôt; Paul B Rosenberg; Nathan Herrmann; David Bachman; Jacobo E Mintzer
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-18       Impact factor: 4.105

9.  The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.

Authors:  Roberta W Scherer; Lea Drye; Jacobo Mintzer; Krista Lanctôt; Paul Rosenberg; Nathan Herrmann; Prasad Padala; Olga Brawman-Mintzer; William Burke; Suzanne Craft; Alan J Lerner; Allan Levey; Anton Porsteinsson; Christopher H van Dyck
Journal:  Trials       Date:  2018-01-18       Impact factor: 2.279

10.  Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Madhukar H Trivedi
Journal:  Int J Neuropsychopharmacol       Date:  2017-11-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.